Additional file 5 of Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective
2020-02-11T05:31:43Z (GMT) by
Additional file 5. Utilities by age and health state. Table showing details of the utility data, by age and health state, included in the model.